CXCR4 to improve both T cell homing and function

detection sequencing (PhasED-seq), a newer methodology with improved detection capacity compared with CAPP-Seq. 10 The investigators showed that baseline ctDNA correlated with disease stage and total metabolic tumor volume, and ctDNA cleared quickly in the large majority of patients treated with APVD.When assessed at cycle 3 day 1 and again at end of treatment, 81% and 92% of patients, respectively, had undetectable ctDNA.The only patient with disease relapse had detectable ctDNA at both time points.Although the numbers are small, the results are provocative and suggest a potential role for ctDNA in response assessment and possibly therapeutic adaptation for patients with cHL treated with frontline PD-1 blockade + chemotherapy.Lynch and colleagues have made an important contribution to the growing body of evidence supporting the efficacy of incorporating PD-1 blockade into frontline treatment of cHL.Since PD-1 blockade when given as monotherapy for cHL is associated with prolonged responses, yet is rarely curative, longer follow-up of this and other similar trials will be important to ensure that remissions are truly durable.Also, further work needs to be done to establish the best way to monitor disease response with these novel regimens given the suboptimal predictive value of PET/CT scans during and following treatment.The use of ctDNA to monitor disease response will need validation in a larger cohort, and the optimal timing of ctDNA sampling also still remains to be determined.Finally, if the striking efficacy results with APVD and other novel anti-PD1-based regimens are maintained in long-term follow-up, then studies of deescalation of therapy, potentially driven by dynamic ctDNA results, could be considered.